Share your videos with the world

Sign Up | Log In | Help  

   
 
Search // 50924
Results 1-1 of 1 for ' 50924 ' (0 seconds)
Dendreon Corporation (Nasdaq: DNDN) announced significant milestones that support broad availability for on-label use of PROVENGE® (sipuleucel-T), the first autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer (mCRPC). To view Multimedia News Release, go to http://www.multivu.com/mnr/50924-dendreon-provenge-cellular-immunotherapy
Categories // Business 
Added: 4228 days ago by MultiVuVideos
Runtime: 3m36s | Views: 9627 | Comments: 1
Not yet rated
 

 

 

Page 1 of 1  |  Go to page   



About Us   |   Help  |   Advertise on ClipMoon   |   Terms of Use   |   Privacy Policy   |   Copyright   |   Contact   |   Link us   |   RSS 
Copyright © 2007-2023 ClipMoon.com. All rights reserved.